Kadın ve Koah İlişkisine Güncel Yaklaşım
Özet
Kadınlarda Kronik Obstrüktif Akciğer Hastalığı (KOAH) prevalansı, tütün ve biyokütle yakıtlarına artan maruziyet nedeniyle erkeklerle eşitlenmiş durumdadır. Kadınlar, sigara ve kirleticilerin zararlı etkilerine karşı biyolojik olarak daha duyarlıdır; daha dar bronşlar ve östrojen hormonu gibi faktörler bu yatkınlığı artırmaktadır. Klinik olarak kadınlar, erkeklerle aynı tıkanıklık derecesinde olsalar bile daha şiddetli nefes darlığı, anksiyete, depresyon ve osteoporoz yaşamakta ve yaşam kaliteleri daha belirgin şekilde bozulmaktadır. Ayrıca, kadınlarda akut solunum atakları ve hastaneye yatış riski daha yüksek olup, hastalık daha genç yaşlarda başlama eğilimindedir. Bu yüksek yüke rağmen, kadın hastalar tanı aşamasında ciddi engellerle karşılaşmaktadır; erkeklere kıyasla daha az spirometri testi yapılmakta, yanlış veya geç tanı oranları yüksek seyretmekte ve yetersiz tedavi uygulanmaktadır. İlaç bazlı tedaviler iki cinsiyette de benzer akciğer fonksiyonu iyileşmesi sağlarken, sigarayı bırakma başarısı kadınlarda uzun vadede daha düşüktür. Sonuç olarak, tıp dünyasında kadın popülasyonuna yönelik klinik farkındalığın artırılması, taramaların yaygınlaştırılması ve bu özel grup için kişiselleştirilmiş, küresel hastalık yönetimi stratejilerinin acilen geliştirilmesi gerekmektedir.
The prevalence of Chronic Obstructive Pulmonary Disease (COPD) in women has equalized with men, driven by increased exposure to tobacco and biomass fuels. Women exhibit greater biological susceptibility to cigarettes and pollutants, influenced by smaller airways and estrogen. Clinically, women experience more severe dyspnea, anxiety, depression, and osteoporosis than men at similar obstruction levels, leading to a profound impairment in their quality of life. Furthermore, women face a higher risk of acute exacerbations and hospitalizations, with the disease manifesting at a younger age. Despite this heavy burden, female patients encounter significant diagnostic biases; they undergo fewer spirometry tests, suffer from higher rates of misdiagnosis, and receive suboptimal treatment compared to men. While pharmacological therapies yield similar lung function improvements across genders, long-term smoking cessation remains more challenging for women. Consequently, there is an urgent global need to enhance clinical awareness, expand targeted screening, and develop personalized disease management strategies specifically designed to address the unique needs of the female population.
Referanslar
Ntritsos G, Franek J, Belbasis L, Christou MA, Markozannes G, Altman P, et al. Gender-specific estimates of COPD prevalence: a systematic review and meta-analysis. Int J Chron Obstruct Pulmon Dis. (2018) 13:1507–14. doi: 10.2147/COPD.S146390
Mannino DM, Buist AS. Global burden of COPD: risk factors, prevalence, and future trends. Lancet. (2007) 370:765–73. doi: 10.1016/S0140-6736(07)61380-4
Jenkins CR, Chapman KR, Donohue JF, Roche N, Tsiligianni I, Han MK. Improving the management of COPD in women. Chest. (2017) 151:686– 96. doi: 10.1016/j.chest.2016.10.031
Chapman KR, Tashkin DP, Pye DJ. Gender bias in the diagnosis of COPD. Chest. (2001) 119:1691–5. doi: 10.1378/chest.119.6.1691
Buist AS, McBurnie MA, Vollmer WM, Gillespie S, Burney P, Mannino DM, et al. International variation in the prevalence of COPD (the BOLD Study): a population-based prevalence study. Lancet. (2007) 370:741–50. doi: 10.1016/S0140-6736(07)61377-4
Silverman M, Pedersen S, Grigg J. Measurement of airway inflammation in children. Introd Am J Respir Crit Care Med. (2000) 162:S1. doi: 10.1164/ajrccm.162.supplement_1.maic-0
Amaral AFS, Strachan DP, Burney PGJ, Jarvis DL. Female smokers are at greater risk of airflow obstruction than male smokers. UK Biobank Am J Respir Crit Care Med. (2017) 195:1226–35. doi: 10.1164/rccm.201608-1545OC
Han MK, Postma D, Mannino DM, Giardino ND, Buist S, Curtis JL, et al. Gender and chronic obstructive pulmonary disease: why it matters. Am J Respir Crit Care Med. (2007) 176:1179–84. doi: 10.1164/rccm.200704-553CC
Jordan RE, Miller MR, Lam KB, Cheng KK, Marsh J, Adab P. Sex, susceptibility to smoking and chronic obstructive pulmonary disease: the effect of different diagnostic criteria. Anal Health Surv Engl Thorax. (2012) 67:600–5. doi: 10.1136/thoraxjnl-2011-201384
Sorheim IC, Johannessen A, Gulsvik A, Bakke PS, Silverman EK, DeMeo DL. Gender differences in COPD: are women more susceptible to smoking effects than men? Thorax. (2010) 65:480–5. doi: 10.1136/thx.2009.122002
Siddharthan T, Grigsby MR, Goodman D, Chowdhury M, Rubinstein A, Irazola V, et al. Association between household air pollution exposure and chronic obstructive pulmonary disease outcomes in 13 low- and middleincome country settings. Am J Respir Crit Care Med. (2018) 197:611–20. doi: 10.1164/rccm.201709-1861OC
Ramírez-Venegas A, Velázquez-Uncal M, Pérez-Hernández R, Guzmán- Bouilloud NE, Falfán-Valencia R,Mayar-MayaME, et al. Prevalence of COPD and respiratory symptoms associated with biomass smoke exposure in a suburban area. Int J Copd. (2018) 13:1727–34. doi: 10.2147/COPD.S156409
Blanc PD, Iribarren C, Trupin L, Earnest G, Katz PP, Balmes J, et al. Occupational exposures and the risk of COPD: dusty trades revisited. Thorax. (2009) 64:6–12. doi: 10.1136/thx.2008.099390
Dumas O, Varraso R, Boggs KM, Quinot C, Zock JP, Henneberger PK, et al. Association of occupational exposure to disinfectants with incidence of chronic obstructive pulmonary disease among US female nurses. JAMA Netw Open. (2019) 2:e1913563. doi:10.1001/jamanetworkopen.2019.13563
Alif SM, Dharmage S, Benke G, Dennekamp M, Burgess J, Perret JL, et al. Occupational exposure to solvents and lung function decline: a population based study. Thorax. (2019) 74:650–8. doi: 10.1136/thoraxjnl-2018-212267
Prescott E, Bjerg AM, Andersen PK, Lange P, Vestbo J. Gender difference in smoking effects on lung function and risk of hospitalization for COPD: results from a Danish longitudinal population study. Eur Respir J. (1997) 10:822–7.
Coxson HO, Dirksen A, Edwards LD, Yates JC, Agusti A, Bakke P, et al. The presence and progression of emphysema in COPD as determined by CT scanning and biomarker expression: a prospective analysis from the ECLIPSE study. Lancet Respir Med. (2013) 1:129–36. doi: 10.1016/S2213-2600(13)70006-7
Roche N, Deslee G, Caillaud D, Brinchault G, Court-Fortune I, Nesme-Meyer P, et al. Impact of gender on COPD expression in a real-life cohort. Respir Res. (2014) 15:20. doi: 10.1186/1465-9921-15-20
Raherison C, Tillie-Leblond I, Prudhomme A, Taille C, Biron E, Nocent-Ejnaini C, et al. Clinical characteristics and quality of life in women with COPD: an observational study. BMC Womens Health. (2014) 14:31. doi: 10.1186/1472-6874-14-31
Zysman M, Burgel PR, Court-Fortune I, Brinchault-Rabin G, Nesme- Meyer P, Surpas P, et al. Relationship between gender and survival in a real-life cohort of patients with COPD. Respir Res. (2019) 20:191. doi: 10.1186/s12931-019-1154-3
DeMeo DL, Ramagopalan S, Kavati A, Vegesna A, Han MK, Yadao A, et al. Women manifest more severe COPD symptoms across the life course. Int J Chron Obstruct Pulmon Dis. (2018) 13:3021–9. doi: 10.2147/COPD.S160270
Aryal S, Diaz-Guzman E, Mannino DM. Influence of sex on chronic obstructive pulmonary disease risk and treatment outcomes. Int J Copd. (2014) 9:1145–54. doi: 10.2147/COPD.S54476
Henoch I, Strang S, Lofdahl CG, Ekberg-Jansson A. Management of COPD, equal treatment across age, gender, and social situation? A register study. Int J Copd. (2016) 11:2681–90. doi: 10.2147/COPD.S115238
EkstromMP, Jogreus C, StromKE. Comorbidity and sex-related differences in mortality in oxygen-dependent chronic obstructive pulmonary disease. PLoS ONE. (2012) 7:e35806. doi: 10.1371/journal.pone.0035806
Bellocchia M, Masoero M, Ciuffreda A, Croce S, Vaudano A, Torchio R, et al. Predictors of cardiovascular disease in asthma and chronic obstructive pulmonary disease. Multidiscip. (2013) 8:58. doi: 10.1186/2049-6958-8-58
Stolz D, Kostikas K, Loefroth E, Fogel R, Gutzwiller FS, Conti V, et al. Differences in COPD exacerbation risk between women and men: analysis from the UK clinical practice research datalink data. Chest. (2019) 156:674–84. doi: 10.1016/j.chest.2019.04.107
Bowler RP, Kim V, Regan E. Prediction of acute respiratory disease in current and former smokers with and without COPD. Chest. (2014) 146:941–50. doi: 10.1378/chest.13-2946
Goto T, Yoshida K, Faridi MK, Camargo CA, Hasegawa K. Contribution of social factors to readmissions within 30 days after hospitalization for COPD exacerbation. BMC PulmMed. (2020) 20:107. doi: 10.1186/s12890-020-1136-8
Molinari N, Chanez P, Roche N, Ahmed E, Vachier I, Bourdin A. Rising total costs and mortality rates associated with admissions due to COPD exacerbations. Respir Res. (2016) 17:149. doi: 10.1186/s12931-016-0469-6
Johansson G, Mushnikov V, Bäckström T, Engström A, Khalid JM, Wall J, et al. Exacerbations and healthcare resource utilization among COPD patients in a Swedish registry-based nation-wide study. BMC Pulm Med. (2018) 18:17. doi: 10.1186/s12890-018-0573-0
Lisspers K, Larsson K, Janson C, Ställberg B, Tsiligianni I, Gutzwiller FS, et al. Gender differences among Swedish COPD patients: results fromthe ARCTIC, a real-world retrospective cohort study. NPJ Prim Care Respir Med. (2019) 29:45. doi: 10.1038/s41533-019-0157-3
Martinez CH, Raparla S, Plauschinat CA, Giardino ND, Rogers B, Beresford J, et al. Gender differences in symptoms and care delivery for COPD. JWomens Health. (2012) 21:1267–74. doi: 10.1089/jwh.2012.3650
Jia G, Lu M, Wu R, Chen Y, Yao W. Gender difference on the knowledge, attitude, and practice of COPD diagnosis and treatment: a national, multicenter, cross-sectional survey in China. Int J Copd. (2018) 13:3269–80. doi: 10.2147/COPD.S176173
Mamary AJ, Stewart JI, Kinney GL, Hokanson JE, Shenoy K, Dransfield MT, et al. Race and gender disparities are evident in COPD underdiagnoses across all severities of measured airflow obstruction. Chron Obstruc Pulmon Dis. (2018) 5:177–84. doi: 10.15326/jcopdf.5.3.2017.0145
Sundh J, Johansson G, Larsson K, Lindén A, Löfdahl CG, Janson C, et al. Comorbidity and health-related quality of life in patients with severe COPD attending Swedish secondary care units. Int J of COPD. (2015) 10:173–83. doi: 10.2147/COPD.S74645
Lamprecht B, Soriano JB, Studnicka M, Kaiser B, Vanfleteren LE, Gnatiuc L, et al. Determinants of underdiagnosis of COPD in national and international surveys. Chest. (2015) 148:971–85. doi: 10.1378/chest. 14-2535
Bade BC, DeRycke EC, Ramsey C, Skanderson M, Crothers K, Haskell S, et al. Sex differences in veterans admitted to the hospital for chronic obstructive pulmonary disease exacerbation. Ann Am Thorac Soc. (2019) 16:707–14. doi: 10.1513/AnnalsATS.201809-615OC
Roche N, Antoniadis A, Hess D, Li PZ, Kelkel E, Leroy S, et al. Are there specific clinical characteristics associated with physician’s treatment choices in COPD? Respir Res. (2019) 20:189. doi: 10.1186/s12931-019-1156-1
Åberg J, Hasselgren M, Montgomery S, Lisspers K, Ställberg B, Janson C, et al. Sex-related differences in management of Swedish patients with a clinical diagnosis of chronic obstructive pulmonary disease. Int J Copd. (2019) 14:961–9. doi: 10.2147/COPD.S193311
Tsiligianni I, RodriguezMR, Lisspers K, LeeTan T, Infantino A. Call to action: improving primary care for women with COPD. NPJ Primary Care Respir Med. (2017) 27:11. doi: 10.1038/s41533-017-0013-2
Tashkin D, Kanner R, Bailey W, Buist S, Anderson P, Nides M, et al. Smoking cessation in patients with chronic obstructive pulmonary disease: a double-blind, placebo-controlled, randomised trial. Lancet. (2001) 357:1571– 5. doi: 10.1016/S0140-6736(00)04724-3
Moore SM, Kramer FM. Women’s and men’s preferences for cardiac rehabilitation program features. J Cardiopulm Rehabil. (1996) 16:163–8. doi: 10.1097/00008483-199605000-00003
Wedzicha JA, Singh D, Tsiligianni I, Jenkins C, Fucile S, Fogel R, et al. Treatment response to indacaterol/glycopyrronium versus salmeterol/fluticasone in exacerbating COPD patients by gender: a post-hoc analysis in the FLAME study. Respir Res. (2019) 20:4. doi: 10.1186/s12931-019-0972-7
Tsiligianni I, Mezzi K, Fucile S, Kostikas K, Shen S, Banerji D, et al. Response to Indacaterol/Glycopyrronium (IND/GLY) by Sex in Patients with COPD: A Pooled Analysis from the IGNITE Program. COPD. (2017) 14:375– 81. doi: 10.1080/15412555.2017.1324837
Blanchette CM, Gutierrez B, Ory C, Chang E, Akazawa M. Economic burden in direct costs of concomitant chronic obstructive pulmonary disease and asthma in a Medicare Advantage population. J Manag Care Pharm. (2008) 14:176–85. doi: 10.18553/jmcp.2008.14.2.176
